Skip to main content

Table 1 Clinicopathological variables in the patients entered into this study

From: p14ARF expression in invasive breast cancers and ductal carcinoma in situ– relationships to p53 and Hdm2

Characteristic No. of patients (%)
Total 103 (100)
Age (years)  
   ≤50 31 (30)
   >50 72 (70)
Invasive tumours  
   Lymph node status  
Negative 37 (41)
Positive 53 (59)
Not assessed 13
   Invasive tumour grade  
Grade I 16 (16)
Grade II 51 (49)
Grade III 36 (35)
   Invasive tumour size (cm)  
≤2 cm 53 (52)
>2 cm 48 (48)
Multifocal 2
   Lymphovascular invasion  
Present 50 (50)
Absent 50 (50)
Not assessed 3
   NPI  
GPG < 3.4 34 (39)
MPG 3.4–5.4 37 (42)
PPG > 5.4 17 (19)
Not possible to calculate 15
   ER (quick-score)  
Positive (4–8) 63 (64)
Negative (0–3) 36 (36)
Not assessed 4
   HER-2 IHC  
Negative (0/1+) 87 (84)
Positive (2+/3+) 16 (16)
   Ki67 IHC  
Low proliferation, <10% 51 (50)
High proliferation, ≥10% 52 (50)
Ductal carcinoma in situ  
   VNPC  
Grade I 23 (24)
Grade II 36 (37)
Grade III 38 (39)
Not assessed 6
   ER (quick-score)  
Positive (4–8) 61 (64)
Negative (0–3) 35 (36)
Not assessed 7
   HER-2 IHC  
Negative (0/1+) 77 (80)
Positive (2+/3+) 19 (20)
Not assessed 7
   Ki67 IHC  
Low proliferation, <10% 61 (59)
High proliferation, ≥10% 42 (41)
  1. ER, oestrogen receptor; GPG, good prognostic group; IHC, immunohistochemistry; MPG, moderate prognostic group; NPI, Nottingham Prognostic Index; PPG, poor prognostic group; VNPC, Van Nuys Pathologic classification.